Posts by Mourabit Halima

The 2024 American Society of Hematology (ASH) Annual Meeting, held from December 7 to 10 in San Diego, continues to be a global focal point for clinicians and researchers in hematology. As one of the most prestigious international conferences in the field, it has captured widespread attention both globally and within China. To provide timely updates on the most significant developments at the conference, Oncology Frontier - Hematology Frontier launched the "ASH Daily News Highlights" series. Dr. Jun Zhu from Peking University Cancer Hospital serves as the series host, connecting daily with onsite experts to bring firsthand updates. On the third day of the conference, we were honored to hear from Dr. Wenming Chen of Beijing Chaoyang Hospital, who shared insights into key studies in the field of myeloma.

Myelodysplastic Syndromes (MDS) are a group of heterogeneous myeloid clonal disorders originating from hematopoietic stem cells, characterized by dysplastic development of myeloid cells, manifested as ineffective hematopoiesis, refractory cytopenia, and the potential to transform into acute myeloid leukemia (AML). At the 2024 American Society of Hematology (ASH) Annual Meeting held in San Diego, USA from December 7th to 10th, numerous studies in the field of MDS were announced, with significant progress particularly in the treatment and prognosis assessment of low-risk MDS. "Hematology Frontier" specially invited Dr. Huaquan Wang from the Department of Hematology, Tianjin Medical University General Hospital, to select and comment on the key studies, in hopes of bringing cutting-edge information and unique insights to everyone.

The 66th Annual Meeting of the American Society of Hematology (ASH) took place from December 7–10, 2024, in San Diego, USA. As the largest and most comprehensive international academic conference in the field of hematology, ASH attracts leading global experts to discuss groundbreaking research and advancements. This year, Dr. He Huang’s team from the Bone Marrow Transplantation Center of The First Affiliated Hospital, Zhejiang University School of Medicine, had 20 studies selected for presentation, including eight as oral presentations. Their achievements not only highlighted their exceptional contributions but also delivered valuable research findings and innovative strategies to the global academic community.

The 2024 Annual Meeting of the American Society of Hematology (ASH) was held from December 7 to 10 in San Diego, USA. As one of the foremost global gatherings in the field of hematology, this prestigious conference attracted the attention of clinicians and researchers worldwide, including a keen audience from China. To bring the latest and most significant updates from the conference to readers promptly, Oncology Frontier - Hematology Frontier launched a special daily column titled ASH News Broadcast · Highlights of the Day. Hosted by Dr. Jun Zhu from Peking University Cancer Hospital, the series connects with on-site experts to deliver firsthand insights. We had the privilege of speaking with Dr. Qian Jiang from Peking University People's Hospital, who shared her thoughts on the key highlights and standout presentations.

The 66th Annual Meeting of the American Society of Hematology (ASH) took place from December 7 to 10, 2024, in San Diego, USA. Renowned as the largest international academic event in hematology, the conference showcased cutting-edge research and the latest advancements in drug development, representing the highest academic standards in the field. At this prestigious event, Dr. Huafeng Wang’s team from The First Affiliated Hospital of Zhejiang University School of Medicine presented four impactful studies. These investigations spanned new therapeutic strategies for myelodysplastic syndrome (MDS) and insights into the mechanisms, potential treatments, and prognostic implications for acute myeloid leukemia (AML). To delve deeper into these findings, Oncology Frontier - Hematology Frontier invited Professor Wang to provide expert commentary and analysis.

Acute myeloid leukemia (AML) remains a major clinical challenge due to its high heterogeneity. While CAR-T cell therapy has shown tremendous success in treating various hematologic malignancies, its application in AML is still in its infancy, necessitating further research and exploration. At the 2024 American Society of Hematology (ASH) Annual Meeting, held from December 7–10, Dr. Mingfeng Zhao from Tianjin First Central Hospital presented groundbreaking findings on a novel iCAR-T therapy for AML, offering renewed hope for patients. Hematology Frontier had the privilege of inviting Prof. Zhao to discuss this study and share insights on his team’s future research plans.

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) was held in San Diego, bringing together global experts and scholars in hematology for an in-depth exploration and exchange of the latest research progress in the field. Among the highlights of this year’s conference were three oral presentations (Oral 94, 238, 367) focusing on CAR-T cell therapy for lymphoma. These studies showcased the latest advancements in CAR-T therapy from three perspectives: enhancing accessibility, optimizing efficacy, and addressing resistance mechanisms. Hematology Frontier invited Dr. Wenbin Qian from The Second Affiliated Hospital of Zhejiang University School of Medicine to provide an in-depth analysis of these three studies, offering valuable guidance and insights for clinical practice.

The 66th American Society of Hematology (ASH) Annual Meeting, held from December 7 to 10, 2024, in San Diego, showcased cutting-edge advancements in hematology. Among the highlights was a study led by Dr. Peihua Lu from the Beijing Lu Daopei Hematology Hospital, presenting Phase I clinical trial results on CD7 CAR-T cell therapy for relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). In this feature, Hematology Frontier invited Professor Lu to share insights into the study's findings, the strategy for expanding CD7 CAR-T indications, and future research plans.

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) was held in San Diego, bringing together global experts and scholars in hematology for an in-depth exploration and exchange of the latest research progress in the field. At this conference, two studies by Dr. Sizhou Feng's team from the Institute of Hematology & Blood Diseases Hospital (Chinese Academy of Medical Sciences) were included for poster presentation (P2127, P2828). "Hematology Frontier" specially invited Dr. Feng to share the research findings and their clinical significance with colleagues at the ASH venue as soon as possible.

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) was held in San Diego, USA, bringing together global experts and scholars in hematology to discuss the latest research developments. At this year’s conference, Dr. Qingqing Cai’s team from Sun Yat-sen University Cancer Center presented two research posters (P3047, P4450), offering novel perspectives and important insights into immunotherapy combinations for relapsed/refractory lymphoma. Hematology Frontier invited Dr. Cai to share the clinical significance and key findings of her team’s research.